1. Home
  2. CKPT vs PTMN Comparison

CKPT vs PTMN Comparison

Compare CKPT & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • PTMN
  • Stock Information
  • Founded
  • CKPT 2014
  • PTMN 2006
  • Country
  • CKPT United States
  • PTMN United States
  • Employees
  • CKPT N/A
  • PTMN N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • PTMN Finance: Consumer Services
  • Sector
  • CKPT Health Care
  • PTMN Finance
  • Exchange
  • CKPT Nasdaq
  • PTMN Nasdaq
  • Market Cap
  • CKPT 172.4M
  • PTMN 142.6M
  • IPO Year
  • CKPT 2017
  • PTMN N/A
  • Fundamental
  • Price
  • CKPT $4.04
  • PTMN $14.15
  • Analyst Decision
  • CKPT Buy
  • PTMN Hold
  • Analyst Count
  • CKPT 3
  • PTMN 1
  • Target Price
  • CKPT $4.33
  • PTMN $16.00
  • AVG Volume (30 Days)
  • CKPT 5.6M
  • PTMN 54.6K
  • Earning Date
  • CKPT 03-28-2025
  • PTMN 03-13-2025
  • Dividend Yield
  • CKPT N/A
  • PTMN 14.97%
  • EPS Growth
  • CKPT N/A
  • PTMN N/A
  • EPS
  • CKPT N/A
  • PTMN N/A
  • Revenue
  • CKPT $41,000.00
  • PTMN $62,432,000.00
  • Revenue This Year
  • CKPT $102,182.93
  • PTMN $6.34
  • Revenue Next Year
  • CKPT $351.71
  • PTMN N/A
  • P/E Ratio
  • CKPT N/A
  • PTMN N/A
  • Revenue Growth
  • CKPT N/A
  • PTMN N/A
  • 52 Week Low
  • CKPT $1.38
  • PTMN $14.15
  • 52 Week High
  • CKPT $4.50
  • PTMN $20.84
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 65.90
  • PTMN 17.80
  • Support Level
  • CKPT $2.37
  • PTMN $14.30
  • Resistance Level
  • CKPT $4.07
  • PTMN $15.69
  • Average True Range (ATR)
  • CKPT 0.03
  • PTMN 0.43
  • MACD
  • CKPT 0.01
  • PTMN -0.16
  • Stochastic Oscillator
  • CKPT 70.00
  • PTMN 1.83

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

Share on Social Networks: